Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte (NYSE American: VTAK), the Regional Air Mobility subsidiary of Catheter Precision, announced a partnership with talent agency GSE Worldwide and PGA TOUR professional Emiliano Grillo, debuting at the 2026 U.S. Open.
The collaboration showcases Flyte’s Cirrus Vision Jet fleet as an efficient regional travel option for elite athletes.
Volato (NYSE American: SOAR) closed a $2.2 million PIPE financing priced at $0.34 per share, issuing 6.5 million common shares. Proceeds are intended to strengthen the balance sheet and support its AI-focused aviation strategy and software-enabled operating platforms.
Strategic investors were led by Catheter Precision, parent of Flyte. The deal builds on Volato’s strategic relationship with Flyte and supports development of its AI assets, including Parslee and Volato AI, while the company evaluates potential acquisitions, mergers, and strategic combinations.
Catheter Precision (NYSE American: VTAK) announced allowance and issuance of multiple patents covering its heart failure and vascular closure technologies. The heart failure portfolio gained six new US patents and two international patents, while vascular closure added one issued US patent and two allowed US applications.
The three vascular closure patents, including US patent no. 12,622,686 dated May 12, 2026, pertain to the LockeT product marketed in the US and Europe. According to the company, these additions expand a library of over fifty patents and support ongoing discussions about the potential sale of these two technologies.
Flyte, the regional air mobility subsidiary of Catheter Precision (NYSE American:VTAK), has joined the Vaunt operator network, a membership-based private aviation platform owned by Volato Group (NYSE American:SOAR).
The partnership gives Flyte’s Cirrus Vision Jet fleet access to Vaunt’s fast-growing member base, creating opportunities to monetize repositioning flights, increase aircraft utilization, and support revenue growth. Vaunt recently reported annual recurring revenue of $3.6 million, up 162% year-over-year. Eligible Vaunt members may receive a $1,000 credit toward qualifying Flyte charters booked directly with Flyte.
Flyte (NASDAQ: VTAK), a regional air mobility company, outlined its activation strategy for the 2026 FIFA World Cup. The plan targets high-value, short-haul travel and brand exposure as millions of visitors move among host cities in the US, Canada, and Mexico.
Flyte is focusing on dense Northeast corridor routes linking New York (HPN/TEB) with Boston (BED), Philadelphia (PNE/TTN), and Washington, D.C. (IAD). Its model emphasizes rapid aircraft repositioning, high-frequency service, same-day flexible scheduling, and group and premium traveler bookings to participate in continuous tournament-related travel demand.
Flyte (NYSE: VTAK), the regional air mobility subsidiary of Catheter Precision, announced a strategic investment in Volato Group (NYSE: SOAR). Flyte acquired about 2.9 million SOAR shares, becoming Volato's largest shareholder with an estimated 7.5% ownership, supporting potential collaboration and growth for both companies.
Volato Group (NYSE American: SOAR) signed a definitive agreement for a $2.2 million strategic investment in restricted common stock, led by Catheter Precision and other institutional investors. The capital is intended to strengthen the balance sheet and support a shift toward AI infrastructure and technology transactions.
The company terminated its prior M2i Global deal and is now evaluating non-binding AI-related letters of intent, while leveraging its existing AI software platform Parslee and the Volato AI initiative. Closing remains subject to NYSE American listing approval and other customary conditions.
Flyte, a subsidiary of Catheter Precision (NASDAQ:VTAK), is deploying its Cirrus Vision Jet fleet across the Northeast for the Belmont Stakes at Saratoga Race Course on June 6, 2026. The high-frequency, short-haul program targets dense, time-sensitive Triple Crown travel demand.
Key routes include NYC (HPN/TEB), East Hampton, and Boston (BED) to Saratoga Springs, with same-day inbound and outbound rotations, group and shared-cabin options, and operations flown by FAA Part 135 carrier Ponderosa Air.
Catheter Precision (NYSE:VTAK) reported Q1 2026 revenue of $432,000, up 200% year-over-year from $143,000, driven by its medical device business and newly acquired Flyte aviation platform.
Net loss improved to $1.7 million from $4.0 million as Flyte rapidly scaled and medical devices expanded globally.
Flyte, a regional air mobility subsidiary of VTAK (NYSE American: VTAK), is deploying aircraft across the Northeast to serve peak travel demand for the Preakness Stakes on Saturday, May 16. Centered on Baltimore/Washington International (BWI), the high-frequency short-haul program targets premium, time-sensitive travelers.
Core routes from New York, Boston, Washington, D.C., and Philadelphia, plus expansion routes from Charlotte and Raleigh-Durham, are structured for dense, rapid-cycle schedules aimed at maximizing aircraft utilization and capturing event-driven revenue opportunities.